WO1999042481A3 - MITTEL ZUR THERAPIE VON MENSCHLICHEN ERKRANKUNGEN, AUSGEHEND VON β-CATENIN, SEINE HERSTELLUNG UND SEINE VERWENDUNG - Google Patents

MITTEL ZUR THERAPIE VON MENSCHLICHEN ERKRANKUNGEN, AUSGEHEND VON β-CATENIN, SEINE HERSTELLUNG UND SEINE VERWENDUNG Download PDF

Info

Publication number
WO1999042481A3
WO1999042481A3 PCT/DE1999/000554 DE9900554W WO9942481A3 WO 1999042481 A3 WO1999042481 A3 WO 1999042481A3 DE 9900554 W DE9900554 W DE 9900554W WO 9942481 A3 WO9942481 A3 WO 9942481A3
Authority
WO
WIPO (PCT)
Prior art keywords
catenin
lef
tcf
peptides
interaction
Prior art date
Application number
PCT/DE1999/000554
Other languages
English (en)
French (fr)
Other versions
WO1999042481A2 (de
Inventor
Walter Birchmeier
Kries Jens-Peter Von
Original Assignee
Max Delbrueck Centrum
Walter Birchmeier
Von Kries Jens Peter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Delbrueck Centrum, Walter Birchmeier, Von Kries Jens Peter filed Critical Max Delbrueck Centrum
Priority to JP2000532433A priority Critical patent/JP2002505255A/ja
Priority to CA002357015A priority patent/CA2357015A1/en
Priority to EP99913097A priority patent/EP1054899A2/de
Publication of WO1999042481A2 publication Critical patent/WO1999042481A2/de
Publication of WO1999042481A3 publication Critical patent/WO1999042481A3/de
Priority to US09/641,104 priority patent/US7067474B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

β-Catenin ist ein zentrales Molekül des Wnt-Signalweges. Erhöhung von β-Catenin in der Zelle führt zur Translokation in den Zellkern und zur Interaktion mit Transkriptionsfaktoren der LEF-1/TCF-Familie. Dies kann zu Kolonkarzinomen und Melanomen führen (onkogener Signalweg). β-Catenin interagiert aber auch mit den Tumorsuppressorgenen APC, Conductin und E-Cadherin, die eine gegenteilige Wirkung auf die Zelle ausüben (anti-onkogene Wirkung). Die Erfindung betrifft von LEF-1-/TCF-4-Transkriptionsfaktoren abgeleitete Peptide und analoge Moleküle in der Tumortherapie, insbesondere zur Behandlung von Kolonkarzinomen und Melanomen. Diese Peptide und analogen Moleküle beeinflussen die Interaktion zwischen β-Catenin und LEF-1/TCF. Anwendungsgebiete der Erfindung sind die pharmazeutische Industrie und die Medizin. Wesentlicher Teil der Erfindung sind Peptide, die Teile der LEF-1-/TCF-4-Transkriptionsfaktoren umfassen, und ihre Varianten und Mutanten. Sie bestehen vorzugsweise aus 10-40 Aminosäuren aus dem N-terminalen Bereich von LEF-1 bzw. TCF-4. Im weiteren umfaßt die Erfindung Peptide oder analoge Moleküle, abgeleitet aus der Armadillo-Region von β-Catenin, die als Interaktionsdomänen zu LEF-1/TCF, APC, Conductin und E-Cadherin identifiziert wurden. Diese Peptide oder analogen Moleküle können ebenso die Interaktion zwischen β-Catenin und LEF-1/TCF hemmen, oder, wie im Falle von APC oder Conductin, die Konzentration von β-Catenin in der Zelle erhöhen. Diese letzteren Moleküle können zur Beeinflussung von Gewebe- und Organbildung, z.B. zur Förderung des Haarwuchses eingesetzt werden.
PCT/DE1999/000554 1998-02-21 1999-02-22 MITTEL ZUR THERAPIE VON MENSCHLICHEN ERKRANKUNGEN, AUSGEHEND VON β-CATENIN, SEINE HERSTELLUNG UND SEINE VERWENDUNG WO1999042481A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000532433A JP2002505255A (ja) 1998-02-21 1999-02-22 βカテニンに基づくヒトの疾患の治療薬、その製造及び使用
CA002357015A CA2357015A1 (en) 1998-02-21 1999-02-22 Agents for treating human illnesses based on .beta.-catenin, and the production and use thereof
EP99913097A EP1054899A2 (de) 1998-02-21 1999-02-22 Mittel zur therapie von menschlichen erkrankungen, ausgehend von beta-catenin, seine herstellung und seine verwendung
US09/641,104 US7067474B1 (en) 1998-02-21 2000-08-17 Agents for treating human illnesses based on β-catenin, and the production and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19807390 1998-02-21
DE19807390.9 1998-02-21

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/641,104 Continuation US7067474B1 (en) 1998-02-21 2000-08-17 Agents for treating human illnesses based on β-catenin, and the production and use thereof

Publications (2)

Publication Number Publication Date
WO1999042481A2 WO1999042481A2 (de) 1999-08-26
WO1999042481A3 true WO1999042481A3 (de) 2000-02-10

Family

ID=7858543

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1999/000554 WO1999042481A2 (de) 1998-02-21 1999-02-22 MITTEL ZUR THERAPIE VON MENSCHLICHEN ERKRANKUNGEN, AUSGEHEND VON β-CATENIN, SEINE HERSTELLUNG UND SEINE VERWENDUNG

Country Status (6)

Country Link
US (1) US7067474B1 (de)
EP (1) EP1054899A2 (de)
JP (1) JP2002505255A (de)
CA (1) CA2357015A1 (de)
DE (1) DE19909251A1 (de)
WO (1) WO1999042481A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1917000A (en) * 1998-11-20 2000-06-13 Arch Development Corporation Regulation of hair follicle morphogenesis based on beta-catenin
WO2000059939A1 (en) 1999-04-05 2000-10-12 Adherex Technologies Inc. COMPOUNDS AND METHODS FOR STIMULATING β-CATENIN MEDIATED GENE EXPRESSION AND DIFFERENTIATION
US6303576B1 (en) 1999-04-21 2001-10-16 Adherex Technologies Inc. Compounds and methods for modulating β-catenin mediated gene expression
AU4314100A (en) * 1999-04-27 2000-11-10 Kyowa Hakko Kogyo Co. Ltd. Transcriptional activation inhibitory protein
DE19944404A1 (de) * 1999-09-16 2001-03-22 Max Delbrueck Centrum Mittel zur Therapie von menschlichen Erkrankungen, insbesondere für die Therapie von Tumoren wie Kolonkarzinomen und Melanomen oder zur Geweberegeneration und Förderung des Haarwuchses
MXPA02008487A (es) 2000-02-29 2002-12-13 Alcon Lab Inc Diagnosticos y terapeutica del glaucoma.
AU5301201A (en) * 2000-03-31 2001-10-15 Gen Hospital Corp Methods of modulating hair growth
CN1321647A (zh) * 2000-04-29 2001-11-14 上海博德基因开发有限公司 一种新的多肽——连环蛋白10和编码这种多肽的多核苷酸
EP1531842A4 (de) * 2000-12-22 2007-03-07 Dana Farber Cancer Inst Inc Regulation des zellwachstums durch muc1
US20040247555A1 (en) * 2002-10-15 2004-12-09 Eli Sprecher Methods of and compositions for modulating hair growth via P-cadherin modulators
EP1830187A1 (de) * 2002-10-15 2007-09-05 Technion Research And Development Foundation, Ltd. Verfahren und Zusammensetzungen zur Haarwuchsmodulierung mittels P-Cadherin-Modulatoren
US7476512B2 (en) 2004-02-27 2009-01-13 The General Hospital Corporation Methods of identifying dermal papilla cells
US9173871B2 (en) 2008-01-28 2015-11-03 New York University Oxazole and thiazole compounds as beta-catenin modulators and uses thereof
US8252823B2 (en) * 2008-01-28 2012-08-28 New York University Oxazole and thiazole compounds as beta-catenin modulators and uses thereof
AU2010298338A1 (en) * 2009-09-22 2012-04-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2012082891A1 (en) 2010-12-14 2012-06-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic peptide inhibitors of wnt pathway
TWI606061B (zh) * 2016-06-14 2017-11-21 高雄醫學大學 用於治療乳癌的細胞穿透胜肽及其應用
CN110194787B (zh) * 2018-02-05 2022-05-17 中国医学科学院药物研究所 靶向抑制Wnt/β-catenin信号活性的多肽及其用途
CN114656549A (zh) * 2022-05-10 2022-06-24 南开大学 基于tip-1-多肽相互作用的新型分子胶水

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996016170A2 (en) * 1994-11-18 1996-05-30 Eisai Co., Ltd. Proteins involved in the regulation of cell-cell adhesion and uses thereof
EP0757994A1 (de) * 1994-12-27 1997-02-12 Snow Brand Milk Products Co., Ltd. Tcf mutanten
WO1998041631A2 (en) * 1997-03-20 1998-09-24 The Johns Hopkins University β-CATENIN, TCF-4, AND APC INTERACT TO PREVENT CANCER
WO1998042296A2 (en) * 1997-03-24 1998-10-01 Onyx Pharmaceuticals, Inc. Compositions and methods for diagnosing/treating disease based on beta-catenin/transcription factor interactions
WO1998045319A2 (en) * 1997-04-10 1998-10-15 Mcgill University COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION BETWEEN α-CATENIN and β-CATENIN

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996016170A2 (en) * 1994-11-18 1996-05-30 Eisai Co., Ltd. Proteins involved in the regulation of cell-cell adhesion and uses thereof
EP0757994A1 (de) * 1994-12-27 1997-02-12 Snow Brand Milk Products Co., Ltd. Tcf mutanten
WO1998041631A2 (en) * 1997-03-20 1998-09-24 The Johns Hopkins University β-CATENIN, TCF-4, AND APC INTERACT TO PREVENT CANCER
WO1998042296A2 (en) * 1997-03-24 1998-10-01 Onyx Pharmaceuticals, Inc. Compositions and methods for diagnosing/treating disease based on beta-catenin/transcription factor interactions
WO1998045319A2 (en) * 1997-04-10 1998-10-15 Mcgill University COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION BETWEEN α-CATENIN and β-CATENIN

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
O. TETSU AND F MCCORMICK: "beta-Catenin regulates expression of cyclin D1 in colon carcinoma cells", NATURE, vol. 398, 1 April 1999 (1999-04-01), LONDON GB, pages 422 - 426, XP002123343 *

Also Published As

Publication number Publication date
WO1999042481A2 (de) 1999-08-26
US7067474B1 (en) 2006-06-27
EP1054899A2 (de) 2000-11-29
JP2002505255A (ja) 2002-02-19
DE19909251A1 (de) 1999-08-26
CA2357015A1 (en) 1999-08-26

Similar Documents

Publication Publication Date Title
WO1999042481A3 (de) MITTEL ZUR THERAPIE VON MENSCHLICHEN ERKRANKUNGEN, AUSGEHEND VON β-CATENIN, SEINE HERSTELLUNG UND SEINE VERWENDUNG
Hida et al. Elucidation of melanogenesis cascade for identifying pathophysiology and therapeutic approach of pigmentary disorders and melanoma
Erickson et al. Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors
Kasai et al. Multifunctional peptide fibrils for biomedical materials
US8759300B2 (en) Polypeptides and methods of use
CY1111120T1 (el) Πεπτιδια που παραγονται απο πρωτεϊνες νευρικων ινων και η ιατρικη τους χρηση
Reiss et al. Mutant p53 tumor suppressor gene causes resistance to transforming growth factor β1 in murine keratinocytes
DE69419958D1 (de) Verwendung des Keratinozyten Wachstumsfaktors (KGF) für die Herstellung von Arzneimitteln
Williams et al. Fibronectin. Effect of disulfide bond reduction on its physical and functional properties.
DE69935078D1 (de) Eine mutante phospholamban moleküle und deren verwendung zur behandlung von herzkrankheiten und herzversagen
JP2001508643A (ja) 抗増殖特性を有するペプチド
CN106265134A (zh) 一种多肽美白修复精华液及其制备方法
Joshi et al. DLC1 SAM domain-binding peptides inhibit cancer cell growth and migration by inactivating RhoA
Sorkin et al. The cadherin-catenin complex is expressed alternately with the adenomatous polyposis coli protein during rat incisor amelogenesis
Sierra-Callejas et al. Primary malignant melanoma of the gallbladder
KR850700008A (ko) 의약용과 미용에 사용되는 조성물의 제조방법
Narayanan et al. Peptides derived from histidine and methionine‐rich regions of copper transporter 1 exhibit anti‐angiogenic property by chelating extracellular Cu
ATE3416T1 (de) Pharmakologisch aktive peptide und diese enthaltende arzneimittel.
DE60019725D1 (de) Verwendung eines mit dem peptid "elagigiltv" assoziierten enterobakterien-proteins ompa zur behandlung von melanomen
Terranova et al. Healing, regeneration, and repair: prospectus for new dental treatment
HRP20041178B1 (hr) Muteini placentalnog faktora rasta tipa 1, metode njihove pripreme i primjene
Tooney et al. Near ultraviolet circular dichroism spectroscopy of plasma fibronectin and fibronectin fragments
CN113995742B (zh) 包含丙戊酸的美白组合物及其用途
CA2388383A1 (en) Agents for treating human diseases, especially for treating tumors such as colonic cancers and melanomas or for regenerating tissue and promoting hair growth
Rosch et al. Impact of pressure and gas type on anastomotic wound healing in rats

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 09641104

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1999913097

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2357015

Country of ref document: CA

Ref country code: CA

Ref document number: 2357015

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1999913097

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1999913097

Country of ref document: EP